Skip to main content Back to Top
Advertisement

6/26/2020

Hydroxyprogesterone Caproate Injection

Products Affected - Description

    • Hydroxyprogesterone caproate intramuscular solution for injection, AuroMedics, 250 mg/mL, 5 mL multiple dose vial, NDC 55150-0310-01
    • Hydroxyprogesterone caproate intramuscular solution for injection, Mylan, 250 mg/mL, 5 mL multiple dose vial, NDC 67457-0886-05

Reason for the Shortage

    • AMAG has Makena vials available.
    • American Regent has hydroxyprogesterone injection available.
    • AuroMedics has hydroxyprogesterone injection available.
    • Mylan did not provide a reason for the shortage.
    • Prasco discontinued the 5 mL vials in mid-2019 and the 1 mL vials in late-2019.
    • Slayback Pharma has hydroxyprogesterone injection available.

Available Products

    • Makena intramuscular solution for injection, AMAG, 250 mg/mL, 1 mL single dose vial, NDC 64011-0247-02
    • Makena intramuscular solution for injection, AMAG, 250 mg/mL, 5 mL multiple dose vial, NDC 64011-0243-01
    • Makena subcutaneous solution for injection, AMAG, 275 mg/1.1 mL, 1.1 mL auto-injector, NDC 64011-0301-03
    • Hydroxyprogesterone caproate intramuscular solution for injection, American Regent, 250 mg/mL, 1 mL vial, NDC 00517-1767-01
    • Hydroxyprogesterone caproate intramuscular solution for injection, AuroMedics, 250 mg/mL, 1 mL single dose vial, NDC 55150-0309-01
    • Hydroxyprogesterone caproate intramuscular solution for injection, Slayback Pharma, 250 mg/mL, 1 mL single dose vial, NDC 71225-0105-01
    • Hydroxyprogesterone caproate intramuscular solution for injection, Slayback Pharma, 250 mg/mL, 5 mL multiple dose vial, NDC 71225-0104-01

Estimated Resupply Dates

    • AuroMedics has short-dated hydroxyprogesterone 250 mg/mL 5 mL vials available.
    • Mylan has hydroxyprogesterone 250 mg/mL 1 mL vials on back order and the company cannot estimate a release date.

Updated

Updated June 26, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 10, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.